Perspective Therapeutics initiated with an Outperform at Scotiabank

Scotiabank initiated coverage of Perspective Therapeutics (CATX) with an Outperform rating and $15 price target The firm says Perspective Therapeutics is one of the few remaining independent radiopharma companies, and believes the recent stock weakness presents a buying opportunity for the shares. Concerns that its neuroendocrine tumor program is not competitive are overdone, says Scotiabank, which thinks the melanoma/FAP-alpha/pre-targeting platform programs are promising but not yet reflected in Perspective’s valuation.